Advanced search
Publication Cover
Future Virology Volume 19, 2024 - Issue 1
Submit an article Journal homepage
158
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Real-life use of High-Dose Anakinra in Patients with COVID-19 Treated with Remdesivir

Roberta Monardo1 Vita-Salute San Raffaele University, via Olgettina 60, 20132, Milan, Italy;2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0002-1388-4322
ORCID Icon,
Andrea Mastrangelo1 Vita-Salute San Raffaele University, via Olgettina 60, 20132, Milan, Italy;2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-6676-8213
ORCID Icon,
Laura Galli2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-8046-0290
ORCID Icon,
Alessandro Tomelleri1 Vita-Salute San Raffaele University, via Olgettina 60, 20132, Milan, Italy;3 Unit of Immunology, Rheumatology, Allergy & Rare Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0002-5440-2078
ORCID Icon,
Vincenzo Spagnuolo2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0002-9656-7217
ORCID Icon,
Chiara Oltolini2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0002-0088-7890
ORCID Icon,
Giacomo Ponta1 Vita-Salute San Raffaele University, via Olgettina 60, 20132, Milan, Italy;2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-6831-2121
ORCID Icon,
Corrado Campochiaro3 Unit of Immunology, Rheumatology, Allergy & Rare Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-6806-3794
ORCID Icon,
Giulio Cavalli1 Vita-Salute San Raffaele University, via Olgettina 60, 20132, Milan, Italy;3 Unit of Immunology, Rheumatology, Allergy & Rare Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-8728-3004
ORCID Icon,
Lorenzo Dagna1 Vita-Salute San Raffaele University, via Olgettina 60, 20132, Milan, Italy;3 Unit of Immunology, Rheumatology, Allergy & Rare Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0002-7428-315X
ORCID Icon,
Fabio Ciceri1 Vita-Salute San Raffaele University, via Olgettina 60, 20132, Milan, Italy;4 Unit of Hematology & Stem Cell Transplantation, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0003-0873-0123
ORCID Icon,
Paola Cinque2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0003-2448-5957
ORCID Icon,
Paolo Scarpellini2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0003-3136-2488
ORCID Icon,
Antonella Castagna1 Vita-Salute San Raffaele University, via Olgettina 60, 20132, Milan, Italy;2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyORCID Iconhttps://orcid.org/0000-0002-8338-9714
ORCID Icon &
Marco Ripa1 Vita-Salute San Raffaele University, via Olgettina 60, 20132, Milan, Italy;2 Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6380-0377
ORCID Icon show all
Pages 11-17 | Received 19 Jul 2023, Accepted 08 Feb 2024, Published online: 26 Feb 2024

References

  • Merad M , BlishCA , SallustoF , IwasakiA. The immunology and immunopathology of COVID-19. Science375(6585), 1122–1127 (2022).
  • Brodin P . Immune determinants of COVID-19 disease presentation and severity. Nat. Med.7(1), 28–33 (2021).
  • Khani E , ShahrabiM , RezaeiH , PourkarimF , AfshariradH , SolduzianM. Current evidence on the use of anakinra in COVID-19. Int. Immunopharmacol.111, 109075 (2022).
  • Rodrigues TS , de SáKS , IshimotoAYet al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med.218(3), e2020–1707 (2021).
  • Kooistra EJ , WaaldersNJB , GrondmanIet al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Crit. Care24(1), 688 (2020).
  • Mehta P , CronRQ , HartwellJ , MansonJJ , TattersallRS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol.2(6), e358–e367 (2020).
  • Kyriazopoulou E , PoulakouG , MilionisHet al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled Phase III trial. Nat. Med.27(10), 1752–1760 (2021).
  • Kharazmi AB , MoradiO , HaghighiMet al. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19. Immun. Inflamm. Dis.10(2), 201–208 (2022).
  • Huet T , BeaussierH , VoisinOet al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol.2(7), e393–e400 (2020).
  • Kyriazopoulou E , HuetT , CavalliGet al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol.3(10), e690–e697 (2021).
  • Cavalli G , DeLuca G , CampochiaroCet al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol.2(6), e325–e331 (2020).
  • Bartoletti M , AzapO , BaracAet al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin. Microbiol. Infect.28(2), 222–238 (2022).
  • COVID-19 Treatment Guidelines Panel . Coronavirus Disease (2019) (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/
  • Beigel JH . What is the role of remdesivir in patients with COVID-19?Curr. Opin. Crit. Care27(5), 487–492 (2021).
  • Olender SA , PerezKK , GoASet al. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin. Infect. Dis.73(11), e4166–e4174 (2021).
  • Monardo R , MastrangeloA , GalliLet al. Real-life use of high-dose anakinra in covid-19 patients treated with remdesivir. Poster presented at Conference on Retroviruses and Opportunistic Infections (CROI).Denver, USA. 12–16 February 2022.
  • CORIMUNO-19 Collaborative group . Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir. Med.9(3), 295–304 (2021).
  • Declercq J , Van DammeKFA , DeLeeuw Eet al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir. Med.9(12), 1427–1438 (2021).
  • Mohamed Hussein AAR , SayadR , AbdelshafiAet al. A meta analysis on the utility of Anakinra in severe COVID-19 disease. Cytokine.169, 156311 (2023).
  • Salliot C , DougadosM , GossecL. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann. Rheum. Dis.68(1), 25–32 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.